Roche Holding AG

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Roche  said Monday it has hired a Massachusetts Institute of Technology (MIT) professor as the new head of the Swiss drugmaker's U.S. research arm that was responsible for some of the company's best-selling medicines of the last few decades.

Roche's U.S. gRED research head to retire, be replaced by MIT's Regev

The new diagnostic tool measures whether a person has developed antibodies for SARS-CoV-2.

FDA Approves Roche's Coronavirus Antibody Test

Severin Schwan, chief executive of Roche, said he believed those who had already had the coronavirus would now be immune to the illness — but he pointed out that more research was required.

Roche CEO says it is 'very likely' patients develop immunity after recovering from coronavirus

Roche says it can make 100 million antibody tests by year's end.

FDA Grants Emergency Authorization To Roche Antibody Tests

Roche  has won emergency approval from the U.S. Food and Drug Administration (FDA) for an antibody test to determine whether people have ever been infected with the coronavirus, the Swiss drugmaker said http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20200503:nGNE71pdqt on Sunday.

Roche wins U.S. nod for COVID-19 antibody test, aims to boost output

Roche Holding AG  received emergency use approval from the U.S. Food and Drug Administration for an antibody test to help determine if people have ever been infected with the coronavirus, the Swiss drugmaker said http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20200503:nGNE71pdqt on Sunday.

Roche gets FDA emergency use approval for COVID-19 antibody test

Hanover Insurance Group Inc (THG) CEO John Roche on Q1 2020 Results - Earnings Call Transcript

Ampio Pharmaceuticals Inc

CytoDyn Inc.

Galectin Therapeutics

Gilead Sciences

Finding The Kink In COVID-19's Armor - Preventing ARDS

Roche Looks Undervalued Given The Stability Of The Business

Roche’s ADR grew over 10% from $40 levels in the beginning of this year to $45 levels as of April 22, compared to a 13% decline for the broader S&P 500. While Roche’s ADR has outperformed the broader markets, we believe there is still 10% upside potential from the current levels.

Is Roche A Buy At $45?

A new COVID-19 test can't overcome slow sales of Roche's drugs and diagnostics.

Roche Increases Sales in the First Quarter: Benefits and Losses From the COVID-19 Pandemic

Solid sales of Roche's (RHHBY) new drugs in the first quarter more than offset the competition from biosimilars.

Roche (RHHBY) Q1 Sales Grow on Solid Performance of New Drugs

The global race to develop a vaccine is on, but getting it to market by the end of 2021 is unlikely, the CEO of the Swiss pharmaceuticals giant suggested on Wednesday.

Coronavirus Vaccine In 12-18 Months Is ‘Ambitious’, Roche CEO Says

Some blood tests being marketed to tell people if they have had the new coronavirus are a "disaster," Roche Chief Executive Severin Schwan said as he prepares to launch the drugmaker's own antibody test next month.

Roche CEO calls some Covid-19 antibody tests a 'disaster' and questions makers' ethics

Some blood tests being marketed to tell people if they have had the new coronavirus are a "disaster", Roche Chief Executive Severin Schwan said on Wednesday as he prepares to launch the drugmaker's own antibody test next month.

'A disaster': Roche CEO's verdict on some COVID-19 antibody tests

Roche's (RHHBY) regulatory applications seeking approval for shorter infusion time for administration of multiple sclerosis drug, Ocrevus, move forward in the United States and Europe.

Roche's Ocrevus Line Extension Application Moves Forward

Roche's (RHHBY) newer drugs are likely to have combated the biosimilar competition for legacy drugs in the first quarter.

Growth in New Drugs to Give a Boost to Roche (RHHBY) Q1 Sales

Roche (RHHBY) develops Elecsys, a new serology test, for the detection of antibodies against SARS-CoV-2, the virus causing COVID-19. The company plans to launch the same early next month.

Roche's New Test to Detect Antibodies to Fight Coronavirus

Abbott Labs

Quest Diagnostics

Labcorp Holdings Inc

Thermo Fisher Scientific

Diagnostic laboratories, rather than the test manufacturers, may be the biggest beneficiaries.

Good News for COVID-19 Testing Companies: Medicare Nearly Doubles Reimbursement

AstraZeneca

Roche AG (RHHBY) moved up to the top spot in the 2020 Pharmaceutical Innovation Index, and for the second year in a row Astra Zeneca (NYSE:AZN) was ranked number one in in the Pharmaceutical Invention Index, according to IDEA Pharma, a New York City-based pharmaceutical consulting firm.

Roche Most Innovative, Astra Zeneca Most Inventive

The FDA stretches the review timeline of Roche's (RHHBY) NDA for risdiplam by three months, which is being evaluated to treat spinal muscular atrophy. A decision is now pending on Aug 24, 2020.

Roche's NDA for SMA Drug Gets Expanded Review From FDA

Regeneron Pharmaceuticals

Clinical data on potential treatments for the new coronavirus could help sustain a market bounce that has buoyed stocks after last month's plunge, as investors look for signs that authorities may be able to stabilize the pandemic.

Investors await data on coronavirus drugs as market rally builds

AbbVie

BioCryst Pharmaceuticals

Biotech Companies In The Race To Find COVID-19 Treatment

Bristol-Myers

Genfit - ADR

Intercept Pharma

Madrigal Pharmaceuticals

Novartis

PTC Therapeutics

The U.S. Food and Drug Administration is scheduled to make decisions on five therapies in the second quarter, and the one that could make the biggest impact on the company and its shares belongs to Intercept Pharmaceuticals Inc.

FDA Decisions on 5 Drugs Expected in 2nd Quarter

If we can test the working population, we will be able to bring the healthy American's back to work and isolate those with the virus

News for Roche Holding AG Stock (RHHBY)